Review article:

HEAT SHOCK PROTEIN 90 TARGETING THERAPY: STATE OF THE ART AND FUTURE PERSPECTIVE

Manabu Tatokoro[1], Fumitaka Koga[2*], Soichiro Yoshida[1], Kazunori Kihara[1]

[1] Department of Urology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan

[2] Department of Urology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan

* Corresponding author: Fumitaka Koga, MD, PhD, Department of Urology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. Phone: +81-3-38232101 Fax: +81-3-38241552
E-mail: f-koga@cick.jp

ABSTRACT

Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that plays a role in stabilizing and activating more than 200 client proteins. It is required for the stability and function of numerous oncogenic signaling proteins that determine the hallmarks of cancer. Since the initial discovery of the first Hsp90 inhibitor in the 1970s, multiple phase II and III clinical trials of several Hsp90 inhibitors have been undertaken. This review provides an overview of the current status on clinical trials of Hsp90 inhibitors and future perspectives on novel anticancer strategies using Hsp90 inhibitors.

Keywords: Hsp90 inhibitor, cancer, clinical trial, bladder cancer

INTRODUCTION

Heat shock protein 90 (Hsp90) is one of the most abundant proteins in eukaryotes, comprising as much as 1 to 2 % of the total cellular protein content under non-stressed conditions, and increasing approximately twofold during environmental stress (Buchner, 1999; Welch and Feramisco, 1982; Whitesell and Lindquist, 2005). In human cells, Hsp90 can be found in the cytosol, nucleoplasm, endoplasmic reticulum and mitochondria (Chen et al., 2005). Beyond Hsp90's essential role in maintaining normal tissue homeostasis, it is an ATP-dependent molecular chaperone that plays a role in stabilizing and activating more than 200 client proteins, many of which are essential for constitutive cell signaling and adaptive responses to stress (Neckers, 2007; Trepel et al., 2010, Whitesell and Lindquist; 2005). The client proteins include oncogenic tyrosine kinase v-Src, mutated oncogene Bcr/Abl, receptor tyrosine kinase of the erbB family and c-MET, and serine/threonine kinase Raf-1 as well as transcription factors such as hypoxia-inducible factor-1α, tumor suppressor p53 protein, and steroid receptors (Koga et al., 2009; Tsutsumi et al., 2009).

CANCER AND HSP90

Cancer is a disease of genetic instability (Neckers, 2007). For example, in colorectal cancers, 5 to 10 genetic alterations appear necessary for the generation of the malignant phenotype, with the classical example of a multistep progression pathway for sporadic carcinoma; however, over 10,000 genomic events per carcinoma have been found at the time of diagnosis (Stoler et al., 1999). The genetic instability allows a cancer cell to ac-

quire the eight hallmarks proposed by Hanahan and Weinberg (2000, 2011). These are (i) self-sufficiency in growth signals; (ii) insensitivity to anti-growth signals; (iii) evading apoptosis; (iv) sustained angiogenesis; (v) tissue invasion and metastasis; (vi) limitless replicative potential; (vii) reprogramming of energy metabolism; and (viii) evading immune destruction. These hallmarks reflect genetic alterations in multiple safeguard genes responsible for the regulation and tight coordination of diverse processes, such as cell survival, proliferation, growth, differentiation, and motility (Sidera and Patsavoudi, 2014). This genetic plasticity allows cancer cells to escape the precise molecular targeting of a single signaling node or pathway, making them ultimately non-responsive to molecularly targeted therapeutics (Neckers, 2007). Each cancer chemotherapeutic has targeted proteins associated with multiple hallmarks, though none have been able to simultaneously affect all of them (Sidera and Patsavoudi, 2014).

Hsp90 consists of a central node in signaling networks and plays a pivotal role in the acquisition and maintenance of each of these capabilities (Neckers, 2007). Therefore, inhibition of Hsp90 leads to the degradation of these oncogenic clients and abrogates the six hallmarks of a cancer cell simultaneously. Therefore, targeting Hsp90 appears to be a reasonable anticancer strategy.

HSP90 INHIBITORS

Hsp90 inhibitors bind to Hsp90 and inhibit Hsp90 function by competing with ATP binding, thereby freezing the chaperone cycle, which in turn decreases the affinity of Hsp90 for client proteins and leads to proteasome-mediated client protein degradation (Tsutsumi et al., 2009). Although Hsp90 is highly expressed in most cells, Hsp90 inhibitors kill cancer cells selectively compared to normal cells (Kamal et al., 2003). This therapeutic selectivity results from the activated, high-affinity chaperone of Hsp90 in tumors (Kamal et al., 2003). Based on the above, Hsp90 has emerged as an exciting and prom-

ising new target for the development of new antineoplastic agents for a variety of human cancers in the last two decades.

In 1970, the benzoquinone ansamycin antibiotics were first isolated (DeBoer et al., 1970). These include geldanamycin (GA), which was found in a search for compounds able to revert the transformed phenotype of v-src transformed 3T3 cells (Whitesell et al., 1992). However, an *in vitro* kinase assay revealed that GA neither directly interacts with Src nor inhibits its phosphorylating activity. Consequently, Hsp90 was identified as the direct target of GA (Whitesell et al., 1994). GA was shown to mimic the structure adopted by ATP in the N-terminal nucleotide-binding pocket of Hsp90, thus leading to selective inhibition of ATP binding and hydrolysis and, in turn, to the depletion of oncogenic Hsp90 clients (Supko et al., 1995). GA alters chaperone function and drives the degradation of many Hsp90 client proteins by stimulating Hsp90-mediated presentation to the ubiquitin–proteasome machinery. Consequently, the client proteins cannot attain their active conformation and are degraded by the proteasome (Mimnaugh et al., 1996). Although GA is broadly cytotoxic *in vitro*, its poor solubility and intolerable liver toxicity *in vivo* precluded clinical trials (Supko et al., 1995). In the last decade, there has been a considerable increase in the discovery of Hsp90 inhibitors, progressing from first-generation derivatives of natural products to second-generation fully synthetic small molecules (Neckers, 2007; Sidera and Patsavoudi, 2014). Less toxic agents than GA, namely, 17-AAG (17-Allylamino-17-demethoxy- geldanamycin) and 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin), have proceeded to clinical trials.

17-AAG (Tanespimycin)

17-AAG was the first Hsp90 inhibitor to enter clinical trials. *In vitro* and *in vivo*, it has shown antitumor activity in various preclinical models, such as colon, breast, ovarian, and melanoma tumors (Neckers, 2007;

Saif et al., 2013). As 17-AAG is not water-soluble and requires a diluent, including egg phospholipid and 4 % DMSO, hypersensitivity reactions were observed in the phase I trial (Whitesell and Lin, 2012). Taken together, several phase II studies of single agent 17-AAG have been performed since 1999 (Gartner et al., 2012; Neckers, 2007; Saif et al., 2013). However, given the lack of response and apparent toxicity, including fatigue, nausea, vomiting, diarrhea, and transaminase elevations, phase II studies in patients with metastatic breast cancer and metastatic melanoma were terminated early (Gartner et al., 2012; Pacey et al., 2012).

17-DMAG (Alvespimycin) and IPI-504 (Retaspimycin)

To overcome the formulation issues with 17-AAG, 17-DMAG (Alvespimycin) and IPI-504 (Retaspimycin) was developed as its water-soluble analog. Alvespimycin is associated with a longer plasma half-life, greater oral bioavailability, and less extensive metabolism (Jhaveri et al., 2012). In preclinical studies, it produced superior antitumor activity and lower toxicity compared with 17-AAG (Eiseman et al., 2005; Jhaveri et al., 2012). A phase I trial of 17-DMAG for advanced solid tumors revealed clinical activity in castration-refractory prostate cancer (complete response), melanoma (partial response), renal cancer, and chondrosarcoma (stable disease) (Pacey et al., 2011). In a phase I trial of 17-DMAG for acute myeloid leukemia (AML), the drug was well tolerated and anti-leukemia activity was observed in 3 of 17 evaluable patients (Lancet et al., 2010). A phase II clinical trial of intravenous 17-DMAG for HER2-positive breast cancer was terminated for unknown reasons (Squibb, 2011).

IPI-504 has reached phase III clinical trials. In a randomized, phase III trial of IPI-504 conducted in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST), the trial was terminated early due to the occurrence of four on-treatment deaths in the IPI-504 arm. These deaths were considered drug-related and included renal failure, liver failure, metabolic acidosis, and cardiopulmonary arrest (Demetri et al., 2010). In contrast, in some phase II studies, including patients with non-small cell lung cancer (NSCLC) (Sequist et al., 2010) and HER2-positive breast cancer (Modi et al., 2013), IPI-504 had an acceptable safety profile, with infrequent transaminase elevations.

Second- and third-generation HSP90 inhibitors

The impressive growth in interest in Hsp90 is evident in both the academic and patent literature and resulted in the discovery and pre-clinical testing of an array of new synthetic inhibitors. Seventeen agents have undergone clinical trials and nine remain under clinical investigation (Neckers and Trepel, 2014). Although no Hsp90-targeting agents have yet achieved an approved indication in the treatment of any cancer, several structurally distinct Hsp90 inhibitors are currently being evaluated for anticancer activity in several phase III clinical trials. These new agents share the ability to bind the N-terminal ATPase site of Hsp90 with higher affinity than the natural nucleotides and prevent the chaperone from cycling between its ADP- and ATP-bound conformations (Whitesell and Lin, 2012). Currently, Hsp90 inhibitors are being evaluated in 52 clinical trials (National Cancer Institute, 2014a). AUY922 (Novartis) and STA-9090 (ganetespib, Synta) are furthest in development (Whitesell and Lin, 2012).

Currently, AUY922 is being evaluated in 13 clinical trials (National Cancer Institute, 2014a), including nine phase II trials in patients with NSCLC, gastrointestinal stromal tumor (GIST), and metastatic pancreatic cancer (Table 1). Common adverse effects of AUY922 have included diarrhea, nausea, fatigue, vomiting, and ocular toxicities (Sessa et al., 2009). In a phase II trial of AUY922 monotherapy in patients with advanced NSCLC, preliminary clinical activity was seen with partial responses in 13 % (Garon et al., 2012). Numerous phase II monotherapy

trials are underway across a variety of malignancies (Whitesell and Lin, 2012).

STA-9090 is an investigational small molecule inhibitor of Hsp90 that has favorable pharmacologic properties that distinguish the compound from other first- and second-generation Hsp90 inhibitors in terms of potency, safety, and tolerability (He et al., 2014). This agent displayed a 20-fold superior potency to 17-AAG in a panel of 57 transformed cell lines of both hematologic

and solid tumors (Ying et al., 2012). It has reached phase III clinical trials and 12 clinical trials are currently underway (National Cancer Institute 2014a) (Table 2). In a multicenter phase II study of STA-9090 monotherapy in patients with advanced NSCLC, durable objective responses and disease stabilization occurred in the majority of patients with disease harboring ALK gene rearrangements that were crizotinib-naïve (Socinski et al., 2013). The most common side

Table 1: Phase II and III trials of AUY922

Study	Phase	Treatment arm(s)	Patient Population	Status
NCT00708292	I/II	AUY922 vs. AUY922 + Bortezomib	Relapsed or Refractory Multiple Myeloma	Completed
NCT01854034	II	AUY922	Non Small Cell Lung Cancer	Recruiting
NCT01484860	II	AUY922	Metastatic Pancreatic Cancer	Terminated
NCT01668173	II	AUY922	Myeloproliferative Neoplasms	Recruiting
NCT01646125	II	AUY922 vs. Docetaxel vs. Pemetrexed	Advanced Non Small Cell Lung Cancer	Recruiting
NCT00526045	I/II	AUY922	Breast Cancer and Hematologic Neoplasms	Completed
NCT01485536	II	AUY922	refractory or recurrent lymphoma	Active, not recruiting
NCT01271920	II	AUY922 + Trastuzumab	Advanced HER2-positive Breast Cancer	Completed
NCT01259089	I/II	AUY922 + Erlotinib	Stage IIIB-IV Non-Small Cell Lung Cancer	Active, not recruiting
NCT01752400	II	AUY922	Advanced ALK-positive NSCLC	Recruiting
NCT01084330	II	AUY922 vs. Docetaxel vs. Irinotecan	Advanced Gastric Cancer	Terminated
NCT01404650	II	AUY922	Refractory Gastrointestinal Stromal Tumor	Recruiting
NCT01402401	II	AUY922 + Trastuzumab	Advanced Gastric Cancer	Terminated
NCT01361945	I/II	AUY922	ER+ HER2+ Advanced Breast Cancer	Withdrawn
NCT01389583	II	AUY922	Gastrointestinal Stromal Tumor	Recruiting
NCT01922583	II	AUY922	Stage IV Non-small Cell Lung Cancer	Recruiting
NCT01124864	II	AUY922	Non-small-cell Lung Cancer	Active, not recruiting
NCT01024283	I/II	AUY922	Advanced Solid Malignancies	Terminated

effects were diarrhea, fatigue, nausea, and anorexia, which have been manageable with standard care. It is notable that, in contrast to AUY922, no ocular toxicity has been reported for STA-9090. The clinical activity of monotherapy was observed in heavily pretreated NSCLC, breast cancer, gastric cancer, melanoma, and colon cancer (Whitesell and Lin, 2012).

COMBINATION ACTIVITY OF HSP90 INHIBITORS

Single agent activity for Hsp90 inhibitors has been disappointingly modest against heavily pretreated cancers in clinical trials that have been reported to date (Trepel et al., 2010; Whitesell and Lin, 2012). Whitesell et al. (2012) suggested this issue might be intrinsic to the target itself and that Hsp90 inhibition could serve as a platform for the assembly of specific multi-drug chemotherapeutic regimens that will more effectively control disparate cancers. Preclinical data from various types of *in vitro* and *in vivo* cancer models suggest that Hsp90 inhibitors have the ability to enhance the activity of other anticancer strategies, including chemotherapy, kinase inhibitors, and radiation therapy, to achieve synergistic or additive antitumor effects, and to potentially overcome drug resistance (Jhaveri et al., 2014). This has formed the basis for rational combination trials of Hsp90 inhibitors with other cancer therapeutic agents.

Chemotherapy

Combinations with several classes of cytotoxic chemotherapeutic agents have now reached clinical trial. Docetaxel has been combined with STA-9090 and IPI-504 in a clinical trial of NSCLC. A phase III trial of STA-9090 in combination with docetaxel versus docetaxel alone in patients with advanced NSCLC is ongoing (Goss et al., 2012). Recently, Synta Pharmaceuticals Corp. announced the results from the final analysis of this trial. For chemo-sensitive patients in particular, the improvements in progression-free survival and overall survival

with STA-9090 and docetaxel were encouraging (Synta Pharmaceuticals Corp., 2014). The phase II randomized trial that evaluated the efficacy and safety of IPI-504 plus docetaxel compared to placebo plus docetaxel in 226 patients with NSCLC was completed. Although the safety profile of IPI-504 plus docetaxel was comparable to docetaxel and placebo, IPI-504 did not meet its pre-specified efficacy endpoints for demonstrating an improvement in overall survival (Infinity Pharmaceuticals, 2013).

Kinase inhibitors

Hsp90 inhibition may also represent an effective strategy to overcome or delay the development of tyrosine kinase inhibitor resistance (Neckers and Trepel, 2014). Preclinical and clinical examples of crizotinib-resistant ALK mutations responding to Hsp90 inhibition have also been reported (Socinski et al., 2013). Furthermore, synergistic growth inhibition in MET-driven tumor models upon combining an Hsp90 inhibitor and a kinase inhibitor targeting this Hsp90-dependent kinase was recently reported (Miyajima et al., 2013). A phase II clinical trial evaluated the safety and efficacy of crizotinib and STA-9090 in ALK-positive lung cancers, and evaluation of the clinical benefit of STA-9090 in combination with sirolimus for patients with unresectable or metastatic malignant peripheral nerve sheath tumor is ongoing (National Cancer Institute, 2014a).

Radiation therapy

Radiation therapy is a well-established standard treatment option for localized and locally advanced cancer. An approach to augment the efficacy of radiation therapy without simultaneously increasing the risk to normal tissues is biologic escalation of the radiation dose to the tumor through the use of tumor-specific radiosensitizing agents (Gandhi et al., 2013). Targeting Hsp90 is a radiosensitizing approach for cancer cells in which Hsp90 is overexpressed compared to normal cells. Hsp90 inhibition offers the

Table 2: Phase II and III trials of STA-9090

Study	Phase	Treatment arm(s)	Patient Population	Status
NCT01579994	I/II	STA-9090 and crizotinib	ALK Positive Lung Cancers	Recruiting
NCT01368003	II	STA-9090	Castration-Resistant Prostate Cancer vs. STA9090 with Dutasteride	Withdrawn
NCT01111838	II	STA-9090	Colon /Rectal Cancer	Completed
NCT01273896	II	STA-9090	Metastatic Breast Cancer	Completed
NCT01270880	II	STA-9090	Castration-Resistant Prostate Cancer	Active, not recruiting
NCT01167114	II	STA-9090	Advanced Esophagogastric Cancer	Active, not recruiting
NCT02008877	I/II	STA-9090 vs. STA9090 with Sirolimus	Malignant Peripheral Nerve Sheath Tumors (MPNST)	Recruiting
NCT01962948	I/II	STA-9090	Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Recruiting
NCT01348126	II/III	STA-9090	Advanced Non Small Cell Lung Cancervs. STA9090 with Docetaxel	Active, not recruiting
NCT01200238	II	STA-9090	Ocular Melanoma	Recruiting
NCT01039519	II	STA-9090	Gastrointestinal Stromal Tumor	Completed
NCT01560416	II	Fulvestrant vs. Fulvestrant with STA-9090	Hormone Receptor-Positive, Metastatic Breast Cancer	Recruiting
NCT01031225	II	STA-9090	Stage IIIB or IV Non-Small Cell Lung Cancer	Active, not recruiting
NCT01227018	II	STA-9090	Metastatic Pancreas Cancer	Terminated
NCT01173523	II	STA-9090	Relapsed or Refractory Small Cell Lung Cancer	Active, not recruiting
NCT01551693	II	STA-9090	Unresectable Stage III or Stage IV Melanoma	Active, not recruiting
NCT01677455	II	STA-9090	Metastatic Breast Cancer	Active, not recruiting
NCT01236144	I/II	STA-9090 vs. Plerixafor vs. AC220	Acute Myeloid Leukemia	Completed
NCT01562015	II	STA-9090	ALK-Positive Non-Small-Cell Lung Cancer	Active, not recruiting
NCT01798485	III	STA-9090	Advanced Non-Small Cell Lung Cancer vs. STA9090 with Docetaxel	Recruiting
NCT02012192	I/II	Paclitaxel vs. STA9090 with Paclitaxel	Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer	Not yet recruiting
NCT01590160	I/II	STA-9090	Malignant Pleural Mesothelioma	Recruiting

possibility of radiosensitization through broad downregulation of multiple critical radioresistance pathways whose components are members of the Hsp90 clientele, such as signal transduction pathways (PI3K-Akt-mTOR) and DNA damage response pathways (ATR/Chk1) (Gandhi et al., 2013). 17-AAG has been validated as a potential therapeutic agent that can be used at clinically relevant doses to enhance cancer cell sensitivity to radiation. 17-AAG has been reported to potentiate both the *in vitro* and *vivo* radiation response of cervical carcinoma cells (Bisht et al., 2003). STA-9090 acts as a radiosensitizer to potentiate the effects of low-dose radiation *in vitro* (He et al., 2014). At the molecular level, it was found that combined Hsp90 inhibition and radiation impacted several overlapping pathways that led to cell cycle dysregulation, diminished DNA repair capacity, and enhanced apoptosis. Currently, a phase I clinical trial of STA-9090 given together with capecitabine and radiation in patients with locally advanced rectal cancer is ongoing (National Cancer Institute 2014a).

HSP90 INHIBITORS IN BLADDER CANCER

For a decade, we have investigated the possibility of the clinical application of HSP90 inhibitors, with a particular focus on bladder cancers. Similar to other malignancies, the single agent activity of Hsp90 inhibitors has been disappointingly modest against bladder cancers and there are no active clinical trials.

Combination of Hsp90 inhibitor in chemoradiotherapy-based bladder-sparing treatment for muscle-invasive bladder cancer

Bladder cancer is the fifth most common cancer in the US, with 74,690 new patients and 15,580 deaths being estimated in 2014 (National Cancer Institute 2014b). Muscle-invasive bladder cancer (MIBC) accounts for one-third of all bladder cancer cases (Lee and Droller, 2000). Radical cystectomy with urinary diversion, the reference standard treatment for MIBC, is associated with high complication rates and compromises quality of life (QOL) as a result of long-term effects on urinary, gastrointestinal and sexual function, and changes in body image. As a society ages, the number of elderly patients unfit for radical cystectomy as a result of comorbidity will increase, and the demand for bladder-sparing approaches for muscle-invasive bladder cancer will thus inevitably increase (Koga and Kihara, 2012). To overcome these issues, bladder-sparing approaches combined with various modalities have been investigated (Housset et al., 1993; Koga et al., 2012; Shipley et al., 2002). Above all, bladder-sparing approaches incorporating chemoradiotherapy (CRT) improves QOL while not compromising survival outcomes in MIBC patients. In most bladder-sparing protocols, complete response to induction CRT is a prerequisite for bladder preservation, also indicating favorable oncological outcomes (Koga et al., 2012, 2008; Rodel et al., 2002: Shipley et al., 1987).

We reported that erbB2 and NFkB overexpression play a potential role in CRT resistance and are independently associated with unfavorable survival with marginal significance in MIBC patients treated with induction CRT plus cystectomy (Inoue et al., 2014; Koga et al., 2011). This indicates that erbB2 and NFkB are putative therapeutic targets for treatments aimed at improving CRT sensitivity in MIBC. Hsp90 inhibitors at low concentrations, which did not exert cytocidal effects but inactivated erbB2, Akt, and NFkB, and efficiently sensitized bladder cancer cells to *in vitro* and *in vivo* CRT more effectively than sole or combined inhibition of erbB2 and Akt (Yoshida et al., 2011).

Based on these results, we sought to examine the potential role of Hsp90 inhibitors in overcoming the CRT resistance and to encourage clinical trials of Hsp90 inhibitors in patients with MIBC. We are planning a clinical trial of STA-9090 in combination with CRT in patients with MIBC.

Combination of Hsp90 inhibitor in cisplatin-based chemotherapy, targeting bladder cancer-initiating cells

Although up to 70 % of patients with advanced bladder cancer show an initially good tumor response to cisplatin (CDDP)-based combination chemotherapy, more than 90 % of patients develop recurrences and eventually die from the disease (Saxman et al., 1997). From the viewpoint of cancer stem cell biology, this phenomenon can be explained as follows: systemic chemotherapy kills the majority of bladder cancer cells, leading to the clinical result of tumor shrinkage; however, a small population of chemo-resistant cancer cells that possess tumorigenic capacity is spared, and they allow tumor regrowth (Dean et al., 2005). The existence of a cellular hierarchy within epithelial tumors has been advocated, and at the top of the hierarchy is a population of tumor-initiating cells (T-ICs) or cancer stem cells. The complete eradication of T-ICs is necessary to ''cure'' advanced cancer patients.

We isolated bladder cancer-initiating cells (BCICs) from human bladder cancer cell lines based on their CD44 expression status (Tatokoro et al., 2012). These BCICs were more resistant to CDDP and exhibited more activity in the Akt and ERK oncogenic signaling pathways when compared with their CD44- counterparts. Hsp90 inhibitors that simultaneously inactivated both Akt and ERK signaling at noncytocidal concentrations synergistically potentiated the cytotoxic effects of cisplatin on BCICs *in vitro* and successfully sensitized cisplatin-resistant BCIC-derived tumor xenografts to cisplatin. These data encourage clinical trials of Hsp90 inhibitors as they may improve therapeutic outcomes of CDDP-based combination chemotherapy against advanced bladder cancer.

FUTURE PERSPECTIVES

Hsp90 drug conjugates as novel cancer-specific anticancer agents

An Hsp90 inhibitor drug conjugate (HDC) platform technology was recently ad-

vocated (Synta Pharmaceuticals, 2014). HDCs increase cancer cell killing while reducing collateral damage to normal cells. They are small-molecule drugs consisting of an Hsp90 inhibitor (targeting moiety) joined to an anti-cancer agent (payload) via a cleavable chemical linker that is optimized for controlled release of the payload drug inside cancer cells (Ying et al., 2014). The active Hsp90 in tumors acts as a magnet to attract the Hsp90-inhibitor moieties in HDCs, bringing the entire HDC molecule preferentially to tumors. This results in higher concentration and longer duration of the active payload drug inside cancer cells than occurs with standard administration of unconjugated chemotherapy or other payloads. The enhanced delivery creates the potential for greater cancer cell killing and reduced side effects.

HDCs with over 40 different payloads have been developed, including chemotherapeutics, kinase inhibitors, hormone therapies, immunomodulators, and epigenetic modifiers, creating the potential for next-generation compounds in each of these categories (Ying et al., 2014). Examples of payloads include topoisomerase inhibitors (camptothecin), microtubule modulators (taxanes), proteasome inhibitors (carfilzomib), and CDK inhibitors (flavopiridol). This innovative approach could have great potential for reducing the adverse effects of existing chemotherapies as well as overcoming drug resistance mechanisms in multiple human malignancies.

REFERENCES

Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003;63:8984-95.

Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci. 1999;24:136-41.

Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics. 2005;86:627-37.

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.

DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot (Tokyo). 1970;23:442-7.

Demetri GD, Le Cesne A, Von Mehren M, Chmielowski B, Bauer S, Chow WA, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. 2010 Gastrointestinal Cancers Symposium. 2010. http://meetinglibrary.asco.org/content/2285-72.

Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dime-thylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol. 2005;55:21-32.

Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, et al. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells. Cancer Biol Ther. 2013;14:347-56.

Garon EB, Moran T, Bariesi F, Gandhi L, Sequist LV, Kim S-W, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 30, 2012;30(Suppl):abstr 7543.

Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, et al. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131:933-7.

Goss GD, Manegold C, Rosell R, Fennell FD, Vukovic VM, El-Hariry I, et al.The GALAXY trial (NCT01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone in subjects with stage IIIB or IV NSCLC. ASCO Annual Meeting. J Clin Oncol. 2012;30(Suppl):abstr TPS7613.

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.

He S, Smith DL, Sequeira M, Sang J, Bates RC, Proia DA. The HSP90 inhibitor ganetespib has chemo-sensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs. 2014;32:577-86.

Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11:2150-7.

Infinity Pharmaceuticals, Inc. Infinity reports topline data from phase 2 study of retaspimycin hydrochloride, its Hsp90 inhibitor, in patients with non-small cell lung cancer. (press release, Sept 25, 2013). http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID=1857866&highlight=)

Inoue M, Koga F, Yoshida S, Tamura T, Fujii Y, Ito E, et al. Significance of erbB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach. Int J Radiat Oncol Biol Phys. 2014;90:303-11.

Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res. 2012;18:5090-8.

Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 2014;14:154-60.

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407-10.

Koga F, Kihara K. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review. Int J Urol. 2012;19:388-401.

Koga F, Yoshida S, Kawakami S, Kageyama Y, Yokoyama M, Saito K, et al. Low-dose chemoradio-therapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis. Urology. 2008;72:384-8.

Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 2009;29:797-807.

Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. ErbB2 and NFkappaB over-expression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One. 2011;6:e27616.

Koga F, Kihara K, Yoshida S, Yokoyama M, Saito K, Masuda H, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int. 2012;109:860-6.

Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010;24:699-705.

Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am. 2000;27:1-13, vii.

National Cancer Institute. Clinical Trials Search. 2014a.
http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=12897579.

National Cancer Institute. SEER Stat Fact Sheets: Bladder Cancer. (7/5 2014). 2014b.
http://seer.cancer.gov/statfacts/html/urinb.html.

Mimnaugh EG, Chavany C, Neckers L. Polyubi-quitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 1996;271:22796-801.

Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res. 2013;73: 7022-33.

Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, et al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2013;139: 107-13.

Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci. 2007;32:517-30.

Neckers L, Trepel JB. Stressing the development of small molecules targeting HSP90. Clin Cancer Res. 2014;20:275-7.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res. 2011;17: 1561-70.

Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S, et al. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 2012;30:341-9.

Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20:3061-71.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71:1345-55.

Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-9.

Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28:4953-60.

Sessa C, Sharma SK, Britten CD, Vogelzang NJ, Bhalla KN, Mita MM, et al. A phase I dose escalation study of AUY922, a novel HSP90 inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2009;27;3532.

Shipley WU, Prout GR, Jr., Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258:931-5.

Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-7; discussion 67-8.

Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014;9:1-20.

Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19:3068-77.

Squibb BM. Phase 2 clinical trial of intravenous alvespimycin [KOS-1022] in patients with Her2 positive breast cancer. Clinical Trials.gov. NLM 2011 Identifier: NCT00780000. . http://www.clinicaltrials.gov/ct2/show/NCT00780000.

Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA. 1999; 96:15121-6.

Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995;36:305-15.

Synta Pharmaceuticals. 2014. HDC Platform. (7/24 2014); http://www.syntapharma.com/hdc-platform.php.

Synta Pharmaceuticals. Corp. SP. Synta announces results from final analysis of the GALAXY-1 trial of ganetespib in NSCLC. 2014 (7/5 2014; http://phx.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1928644&highlight=.

Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, et al. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 2012;131:987-96.

Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537-49.

Tsutsumi S, Beebe K, Neckers L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol. 2009;5:679-88.

Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem. 1982; 257:14949-59.

Whitesell L, Lin NU. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochim Biophys Acta. 2012;1823:756-66.

Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761-72.

Whitesell L, Shifrin SD, Schwab G, Neckers LM. Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 1992;52:1721-8.

Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994;91:8324-8.

Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012;11:475-84.

Ying W, Chimmanamada D, Zhang J, Przewloka T, Jiang J, Lu G, et al. Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation. Cancer Res. 2014;74:1619.

Yoshida S, Koga F, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle. 2011;10:4291-9.